CD44 variant antibodies and kit for characterizing and isolating cancer stem cells : Citations

 

Ordering Information

Name	Catalog Number	Host	Reactivity	Clone	Applications
Anti CD44 v10-e16	CAC-LKG-M002 CAC-LKG-M002S	RT	MS	RM1	FC IHC
Anti CD44 v9	CAC-LKG-M001 CAC-LKG-M003	RT	HU	RV3	FC WB IHC(p) IF ELISA IP MACS Photo-immunotherapy
Magnetic Cell separation Kit for Human CD44v9+ Cancer Stem Cell	CSR-CSC-SEP1	RT	HU	RV3	Cancer stem cell isolation

Year	Publications citing anti-CD44 splice variant clones RM1 and RV3 or CD44 ICD rabbit polyclonal	Click for citation
2019	Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells. 2019. Cell Communication and Signaling 17:80. Anti-human CD44-ICD antibody (Rabbit polyclonal available from Cosmo Bio) was used in western blot analysis of prostate cancer cell lines (PC3, LnCaP and PCa2b). A previous study of breast cancer cells showed that a CD44-ICD/RUNX2 complex occurred on the metastasis-related MMP-9 gene promoter region. This study shows a functional relationship between CD44-ICD and RUNX2 in the prostate cancer cell line PC3. Elevated RUNX2 expression in PC3 cells was associated with increased nuclear CD44-ICD/RUNX2 interaction and expression of MMP-9 as well as increased migration and tumorsphere formation.	PMID
2019	Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer. 2019. Cancer Science. 110:1431–1441. Anti-human CD44v9 antibody (clone RV3 available from Cosmo Bio) was used in immunohistochemical analyses of radical cystectomies from muscle invasive bladder cancer (MIBC) patients. CD44v9 expression was independently associated with disease recurrence and cancer-specific death in MIBC. Cytotoxic effects, glutathione levels, and reactive oxygen species production by sulfasalazine (SSZ) and CD44v9 and phospho-p38 MAPK protein expression by SSZ with or without cisplatin (CDDP) were assessed in MBT-2V cells with highly metastatic potential. SSZ exerted cytotoxic effects against MBT-2V cells by inhibiting glutathione levels and inducing the production of reactive oxygen species. SSZ in combination with CDDP appeared to exert strong cytotoxic effects against MBT-2V cells by inhibiting CD44v9 expression and upregulating phospho-p38 MAPK expression. The inhibitory effects of SSZ with or without CDDP were also investigated using an MBT-2V lung metastatic model. In the murine lung metastatic BC model, SSZ significantly prolonged animal survival. Furthermore, the combination of SSZ with CDDP exerted stronger inhibitory effects on the establishment of lung tumor nodules than SSZ or CDDP alone.	PMID
2019	Cancer stem-cell marker CD44v9-positive cells arise from Helicobacter pylori-infected CAPZA1-overexpressing cells. 2019. Cellular and Molecular Gastroenterology and Hepatology. 8(3):319 - 334. Anti-human CD44v9 antibody (clone RV3 available from Cosmo Bio) was used in immunohistochemical and western blot analyses of Mongolian gerbil gastric mucosa, human gastric adenocarcinomas and the gastric cancer cell lines (MKN28 and AGS). This paper demonstrates the role of CAPZA1 in CD44v9 expression and shows that the presence of CAPZA1-overexpressing cells induces expansion of CD44v9-positive cells. The induction of CD44v9 expression in CAPZA1-overexpressing cells infected with H pylori is caused by aberrant beta-catenin signaling via intracellularly accumulated CagA and by alternative splicing of CD44 total via overexpression of ESRP1. Accumulation of CagA in CAPZA1-overexpressing cells also aberrantly induced SALL4 and KLF5 expression. These findings show that over-expression of CAPZA1, in combination with accumulation of CagA, predisposes cells to develop into CD44v9-positive cells in H pylori–infected gastric mucosa.	PMID
2018	Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013 32(44):5191-8. This review paper describes the discovery of a critical association between a variant form of CD44 (CD44v8-10; recognized by clone RV3 available from Cosmo Bio) and xCT, a subunit of the cystine-glutamate antiporter required for generation of intracellular antioxidant GSH. CD44v8-10 is thought to be a cancer stem cell marker that acts in part by promoting resistance to ROS, thereby accounting for enhanced resistance to chemo and radiotherapy.	PDF
2018	Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers. Sci Rep. 2018 8(1):2291. Anti-mouse CD44v monoclonal Ab (Cosmo Bio) was used in immunohistochemical analysis of gastric epithelia and gastric epithelial tumor cells. By 20 weeks of age mice whose gastric mucosa overexpressed Wnt1, Cox2 and microsomal prostaglandin E synthase-1 (Gan mice) developed dysplastic gastric tumors of low malignancy. In this paper the authors crossed Gan mice with p53 KO mice to produce p53 deficient Gan mice. Gastric epithelial cells from p53 KO Gan mice were tumorigenic when transplanted into immunocompetent recipients and serial transfers gradually gave rise to malignant gastric cancer. CD44v expression was noted to increase in p53 KO Gan mouse gastric tumors but to diminish in undifferentiated portions of highly malignant serially transferred tumors.	PDF
2018	Regulation of Gastric Lgr5+ve Cell Homeostasis by Bone Morphogenetic Protein (BMP) Signaling and Inflammatory Stimuli. Cell Mol Gastroenterol Hepatol. 2018 5(4):523-538. Anti-mouse CD44v10-e16 rat monoclonal Ab (clone RM1 available from Cosmo Bio) was used in immunohistochemical staining of mouse gastric epithelium. Evidence is presented that impaired BMP signaling coupled with Helicobacter felis infection leads to loss of parietal cells and to activation and expansion of a subset of Lgr5 positive chief cells that express CD44v9, a cancer stem cell marker of SPEM known to give rise to gastric carcinogenesis.	PDF
2018	Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. Cancer. 2018 18(1):113. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemistry of human urothelial cancer tissue and in immunofluorescence staining of human bladder cancer cell lines. Positivity for CD44v9 (CD44v8-10) was shown to be associated with a significantly higher incidence of high grade urothelial tumors. Further, positivity for CD44v9 (CD44v8-10) was also shown to be a strong prognostic indicator of poor cancer specific survival in UC patients treated with CDDP-based chemotherapy and also found to be a significant risk factor for cancer specific mortality.	PMID
2018	Prominent role of RAB39A-RXRB axis in cancer development and stemness. Oncotarget. 2018 9(11): 9852–9866. Using global expression profiling of human osteosarcoma cells and normal fibroblast cell lines, RAB39A was discovered to be a functional cancer stem cell marker whose knockdown and overexpression correlated with loss and gain of in vitro sphere-forming and in vivo xenograft tumor forming ability. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in flow cytometry of sarcoma cell lines to show that knockdown of RAB39A led to a decrease in the expression of CD44v9. Differential global expression profiling of RAB39A knockdown spheres led to the identification of RXRB as a major downstream effector of RAB39A, suggesting both molecules as therapeutic targets in cancer cells.	PDF
2017	Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma. J Cancer. 2017 8(10):1774-1785. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemistry and flow cytometry to screen multiple lung cancer cell lines for properties associated with cancer stem cells (CSCs). Staining for aldehyde dehydrogenase (ALDH) was also combined with CD44v9 with the hope of improving the ability to detect CSCs. The results suggest that CD44v9 is a good marker for lung CSCs in human lung adenocarcinoma cell lines. Use of ALDH as second marker provided evidence that lung CSCs may be heterogeneous with different CSC properties distributed over distinct cell subsets.	PMID
2017	CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer. Sci Rep. 2017 7(1):4930. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used to demonstrate predominant expression of CD44v8-10 in gastric cancer cell lines and advanced gastric tumors. CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was conjugated with near infrared red (NIR) fluors ATTO680 for immunohistochemical detection of CD44v8-10-expressing cells in gastric tumor tissues; and Methylene Blue (MB) for use in in vitro photoimmunotherapy. MB causes not only NIR fluorescence, but also the highly efficient generation of singlet oxygen, thereby selectively killing cancer cells. In mixtures of cell lines either expressing CD44v8-10 or not and stained with MB-conjugated CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) only the CD44v8-10-expressors were subject to photolysis. Together, the results suggest the applicability of CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) for NIR fluorescence detection and photoimmunotherapy of both primary gastric cancer cells and disseminated cancer stem cell-like CD44v8-10(+) cells in the peritoneal cavity in advanced gastric cancer.	PMID
2017	Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer. Int J Oncol. 2017 51(3):771-780. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in flow cytometry to sort and analyze the human gall bladder cancer cell line NOZ. The NOZ cell line is shown to comprise two populations that express different CD44 isoforms: CD44s and CD44v9, accounting for 70% and 30% of the CD44+ cells, respectively. Interestingly, the CD44s cells exhibited elevated migration and invasion phenotypes and expressed mesenchymal markers ZEB1, ZEB2 and Vimentin while the CD44v9 cells did not. Instead, they exhibited enhanced tumorigenicity in a mouse xenograft model and expressed high levels of the epithelial marker E-cadherin and the splicing factor ESRP1. Also, subculture of CD44v9 cells gave rise to both CD44v9 and CD44s cells, while subculture of CD44s cells only gave rise to CD44s cells.	PMID
2017	SIRT1 Regulates the Chemoresistance and Invasiveness of Ovarian Carcinoma Cells. Transl Oncol. 2017 10(4): 621–631. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunoblot assays to show that SIRT1 upregulates CD44v9 in ovarian carcinoma cells, correlating with acquisition of enhanced resistance to oxidative stress. Genetic and pharmacological knockdown of SIRT1 downregulated CD44v9 while upregulation led to enhanced CD44v9. The cancer stem cell marker CD44v9 is known to be involved in stabilizing the xCT glutamate-cystine antiporter system that promotes GSH production and protection from ROS.	PMID
2017	Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Cancer Sci. 2017 108(9):1843-1849.  Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used to show that effectiveness of salazosulfapyridine treatment in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer was associated with an increase in serum CD44v9, likely due to apoptotic death of CD44v9+ CSC. Serum samples collected from 14 patients before and after 21 days of salazosulfapyridine treatment were tested by ELISA for human CD44v9 (clone RV3 available from Cosmo Bio).	PMID
2017	cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells. J Control Release. 2017 Sep 10;261:275-286. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemical and flow cytometric analyses to confirm the expression of αvβ5 integrins on the CD44v-positive fractions of two human oral carcinoma cells (HSC-2 and SAS-L1). By installing the αvβ5 integrin-targeting cyclic Arg-Gly-Asp (cRGD) peptide on the surface of cisplatin (CDDP)-containing micelles (CDDP/m), therapeutic strategies were tested for improved efficacy against head and neck squamous cell cancer (HNSCC)-bearing cancer stem cells (CSCs). cRGD-installed CDDP/m (cRGD-CDDP/m) exhibited significant antitumor activity against both orthotopic HSC-2 and SAS-L1-Luc tumors, and rapidly and selectively accumulated in lymph node metastases of the SAS-L1-Luc tumor and reduced their growth rate.	PMID
2017	Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression. Cell Death Dis. 2017 8(6): e2857. Ultra low molecular weight hyaluronan is shown to induce features consistent with necrotic cell death in B-precursor leukemia cells that express high levels of CD44. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in flow cytometry to show that this property did not correlate with the magnitude of ultra-low molecular weight hyaluronan-mediated inhibition of leukemic cells.	PMID
2017	Increased Expression of CD44v9, A Cancer Stem Cell Marker, in Head And Neck Squamous Cell Carcinoma Cells after Irradiation. 2017 Int J Cancer Oncol. 4(2): 1-5. FITC-conjugated anti-human CD44s clone SFF-2, APC-conjugated anti-human CD44v9 (clone RV3 available from Cosmo Bio), APC-conjugated anti-human CD44v3 clone 3G5 and APC-conjugated anti-human CD44v6 clone 2F10 were used in flow cytometry on 5 different human squamous cell carcinoma cell lines to show that after exposure to 60 Gy of irradiation expression of CD44s decreased while variant CD44 expression increased, especially CD44v9. These changes correlated with increased sphere forming ability.	PDF
2017	Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis. United European Gastroenterol J. 2017 5(1):37-44. Anti-human CD44v9 rat monoclonal Ab (clone RV3 from Cosmo Bio) was used in immunohistochemistry to show that patients suffering from either autoimmune or adenocarcinoma-associated chronic atrophic gastritis exhibited elevated CD44v9 expression in spasmolytic polypeptide-expressing metaplastic (SPEM) tissue.	PMID
2017	CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues. Biomed Res. 2017 38(1):41-52. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemistry to analyze 103 gastric cancer patient specimens for CD44v9 expression and correlation with five-year recurrence-free survival rate and metabolomic analysis. The results show that high level expression of CD44v9 correlated with significantly lower five-year recurrence-free survival rate and reduced glutathione disulfide levels.	PMID
2017	A signalling cascade of IL-33 to IL-13 regulates metaplasia in the mouse stomach. Gut. 2018 67(5):805-817. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunocytochemical analyses to identify spasmolytic polypeptide-expressing metaplasia (SPEM) in the stomach by quantitating the number of cells triple-positive for GSII-lectin, CD44v9 and gastric intrinsic factor (GIF). The authors conclude: Metaplasia induction and macrophage polarization after parietal cell loss is coordinated through a cytokine signaling network of IL-33 and IL-13, linking a combined response to injury by both intrinsic mucosal mechanisms and infiltrating M2 macrophages.	PMID
2017	Targeted Apoptosis of Parietal Cells Is Insufficient to Induce Metaplasia in Stomach. Gastroenterology. 2017 152(4):762-766.e7. Anti-mouse CD44v10-e16 (clone RM1 available from Cosmo Bio), ortholog of human v9, was used in IHC(p) to characterize mouse stomach. To test whether parietal cell atrophy causes metaplasia in the stomach, mice that expressed the diphtheria toxin receptor specifically in parietal cells to induce their death, were found to exhibit elevated proliferation in the normal stem cell zone and neck but not metaplastic reprogramming of chief cells.	PMID
2016	Comparable roles of CD44v8-10 and CD44s in the development of bone metastases in a mouse model. Oncol Lett. 2016 12(4):2962-2969. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunoblots to confirm the overexpression of CD44v8-10 in lung and breast cancer cell lines. No significant difference was detected in the phenotype of cell lines transfected to overexpress CD44s versus CD44v, in terms of in vitro invasiveness, migration, and tumor sphere formation or on the development of bone metastases.	PMID
2016	Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer. Oncol Rep. 2016 36(5):2852-2860. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemistry to assess CD44v9 expression in 98 pathologically confirmed bladder tumor specimens and in two human bladder cancer cell lines. Expression was then correlated with clinical outcome. Elevated CD44v9 expression was correlated with significantly lower progression free and cancer-specific survival rates. In vitro siRNA knockdown of CD44v9 led to lower invasion ability and shorter migration distance, increased expression of the epithelial marker E-cadherin and decreased expression of EMT markers N-cadherin, Snail and Slug.	PMID
2016	Calreticulin is highly expressed in pancreatic cancer stem-like cells. Cancer Sci. 2016 107(11):1599-1609. CD44v9-expressing cells from pancreatic cancer cell lines were magnetically enriched using anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) with MACS (Miltenyi) and sorted/analyzed by flow cytometry. Resected pancreatic tumor samples were analyzed by immunohistochemistry for CD44v9-expression. Interestingly, CD44v9 level showed no correlation with clinical outcome.	PMID
2016	CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS One. 2016 11(6):e0156595. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemical analysis of a tumor microarray comprising high-grade serous ovarian cancer biopsies. CD44v9 positivity correlated positively with survival. Elevated CD44v9 expression was also shown to correlate with markers of epithelial phenotype, including EPCAM, ESPR1 and E-cadherin.	PMID
2016	CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment. Cancer Sci. 2016 107(7):991-1000. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemistry and flow cytometry to study CD44 expression in a hamster cholangiocarcinogenesis model and in human cholangiocarcinomas. CD44v8-10 expression inferred from anti-CD44v9 staining was shown to correlate with survival of patients with Opisthorchis viverrini-associated cholangiocarcinoma. Elevated CD44v9 expression also correlated with expression of xCT (part of the glutamate/cystine antiporter important for regeneration of glutathione) and intracellular GSH and downregulation of p38 MAPK-mediated responses to oxidative stress.	PMID
2016	Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality. Urol Oncol. 2016 34(8):337.e19-26. Anti-human CD44v9 (clone RV3 available from Cosmo Bio) was used in IHC(p) to characterize upper tract urothelial cancer (UTUC) in 110 patients. Immunohistochemical expression of CD44v9 was correlated with clinical features and oncological outcomes. A multivariate analysis revealed CD44v9 expression as an independent risk factor for cancer-specific survival in addition to tumor grade G3, and also for recurrence-free survival, in addition to tumor grade G3 and lymphovascular invasion.	PMID
2016	Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines. Journal of Controlled Release. 2016 230:26-33. Anti-human CD44v9 (clone RV3 available from Cosmo Bio) was used in IHC(p) to characterize CD44v9 expression by HSC2 human squamous carcinoma cells in murine subcutaneous and orthotopic xenograft tumor models. The study demonstrates the ability of a micelle-based nanomedicine incorporating cisplatin (CDDP/m) to eradicate both undifferentiated and differentiated cancer cell populations in tumors arising in head and neck tumor models.	PMID
2016	CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma. Cancer Sci. 2016 107(5):609-18. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) and anti-mouse CD44v8-10 (CD44v10-e16 RM1 available from Cosmo Bio) used in immunohistochemical analyses of hepatocellular carcinomas from 90 hepatitis C virus positive patients as well as in diethylnitrosamine-induced hepatocellular carcinomas in C57BL/6 mice. CD44v9 positive cells were predominantly negative for Ki67 and phospho-p38 MAPK expression. CD44v9 expression correlated with poor overall and recurrence-free survival.	PMID
2016	Lipocalin 2 attenuates iron-related oxidative stress and prolongs the survival of ovarian clear cell carcinoma cells by up-regulating the CD44 variant. Free Radic Res. 2016 50(4):414-25. Lipocalin 2 (LCN2) is a multi-functional secretory protein that functions as an iron transporter as well as an antioxidant. Anti-human CD44v9 (clone RV3 available from Cosmo Bio) was used in western blot and immunofluorescence analyses of ovarian clear cell carcinoma cell lines exposed to elevated levels of LCN2. The study shows that CD44v protein expression was increased by the addition of rLCN2 and by forced expression of LCN2.	PMID
2016	Expression of Activated Ras in Gastric Chief Cells of Mice Leads to the Full Spectrum of Metaplastic Lineage Transitions. Gastroenterology. 2016 150(4):918-30.e13. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemistry to characterize spasmolytic polypeptide expressing metaplastic (SPEM) tissue induced in the stomach by enforced expression of Kras in Chief cells.	PMID
2016	Immunohistochemical analyses of CD44 variant isoforms in invasive micropapillary carcinoma of the breast: comparison with a concurrent conventional invasive carcinoma of no special type component. Breast Cancer. 2016 23(6):869-875. xxx	PMID
2015	Clinicopathological characterisation of duodenal adenocarcinoma with high CD44 variant 9 expression. Pathology. 2015 47(7):647-52. Anti-human CD44v9 (clone RV3 available from Cosmo Bio) was used in IHC(p) to characterize CD44v9 expression in duodenal adenocarcinoma samples. The study shows that CD44v9 positivity correlates with diminished positivity for Ki-67 and cleaved caspase 3. Taken together, the authors suggest that CD44v9 positive cells in duodenal adenocarcinoma possess low mitotic activity and the ability to resist apoptosis, consistent with a cancer stem cell-like phenotype.	PMID
2015	Induction of CD44 Variant 9-Expressing Cancer Stem Cells Might Attenuate the Efficacy of Chemoradioselection and Worsens the Prognosis of Patients with Advanced Head and Neck Cancer. PLoS ONE. 2015 10(3): e0116596. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in immunohistochemical analyses to screen head and neck tumors from patients that had undergone or not combined chemoradioselection therapy. CD44v9 positivity was significantly correlated with poor prognosis. Furthermore, the survival rate of the CD44v9-induced group was significantly worse than the CD44v9-non-induced group.	PMID
2015	Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis. Exp Mol Pathol. 2015 98(1):41-6. Anti-human CD44v9 (clone RV3 available from Cosmo Bio) was used in immunofluorescence analysis to characterize CD44v9 expression in pancreatic cancer cell lines (CI-24, PCI-43, PCI-55, PANC-1 and MIA PaCa2) representing epithelial- and mesenchymal-phenotypes. Epithelial phenotype (E-cadherin+) pancreatic cell lines expressed high levels of CD44v9 and multidrug resistance protein 1 (MDR1). By contrast, mesenchymal phenotype (Vimentin+ and ZEB1+) pancreatic cell lines expressed low levels of CD44v9.	PMID
2015	Chronic inflammation with Helicobacter pylori infection is implicated in CD44 overexpression through miR-328 suppression in the gastric mucosa. J Gastroenterol. 2015 50(7):751-7. xxx	PMID
2014	Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer. 2014 14:722. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in flow cytometry to characterize a neural survival factor1 (NSF-1)-supplemented short-term sphere cell culture system that could convert two distinct hepatocellular carcinoma cell lines (one poorly differentiated and the other undifferentiated) into slowly proliferating cancer stem-like cells expressing CDD4v9 and other stem cell markers (Nanog and Lin28) and exhibiting diminished ROS, elevated Hif1a expression and enhanced resistance to a panel of anti-cancer drugs.	PMID
2013	Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013 32(44):5191-8. This review paper describes the discovery of a critical association between a variant form of CD44 ( CD44v8-10; recognized by clone RV3 available from Cosmo Bio) and xCT, a subunit of the cystine-glutamate antiporter required for generation of intracellular antioxidant GSH. CD44v8-10 is thought to be a cancer stem cell marker that acts in part by promoting resistance to ROS, thereby accounting for their enhanced resistance to chemo and radiotherapy.	PDF
2012	Reactive oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells. Cell Host Microbe. 2012 12(6):764-77. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was used in flow cytometry to delineate expression of CD44v9 by CD44 negative MKN28 cells transfected with CD44v9 or CD44s, prior to assessing their response to infection with Helicobacter pylori. Anti-human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio) was also used in fluorescent immunohistochemistry on patient derived gastric adenocarcinomas.	PMID
2012	Anti-Tumor Effect against Human Cancer Xenografts by a Fully Human Monoclonal Antibody to a Variant 8-Epitope of CD44R1 Expressed on Cancer Stem Cells. PLoS ONE. 2012 7(1): e29728. This is one of 3 papers where a description can be found of the construction of human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio). Female F344 rats were repeatedly injected subcutaneously and intraperitoneally with RH7777 cells expressing human CD44v8-10 linked to green fluorescent protein. Specificity was assessed by enzyme-linked immunosorbent assay using the recombinant variant exon-9 region of the CD44v protein. The study describes the construction and validation of: GV5 (fully humanized) IgG mAb against CD44v8 RV7 rat mAb against human CD44s RV9 rat mAb against human CD44v8 GV5 is shown to inhibit the growth of human cancer xenografts in athymic mice.	PMID
2011	CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011 19(3):387-400. This is one of 3 papers where a description can be found of the construction of human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio). Female F344 rats were repeatedly injected subcutaneously and intraperitoneally with RH7777 cells expressing human CD44v8-10 linked to green fluorescent protein. Specificity was assessed by enzyme-linked immunosorbent assay using the recombinant variant exon-9 region of the CD44v protein. This landmark study shows that high levels of CD44v8-10 expressed on gastrointestinal tumor cells confer elevated intracellular GSH and resistance to damage from ROS. This is due to CD44v8-10-dependent recruitment of the xCT subunit of the System xc- antiporter responsible for importing cystine in exchange for glutamate, critical for the regeneration of GSH.	PMID
2010	CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis. Cancer Sci. 2010 101(3):673-8. This is one of 3 papers where a description can be found of the construction of human CD44v9 rat monoclonal Ab (clone RV3 available from Cosmo Bio). Female F344 rats were repeatedly injected subcutaneously and intraperitoneally with RH7777 cells expressing human CD44v8-10 linked to green fluorescent protein. Specificity was assessed by enzyme-linked immunosorbent assay using the recombinant variant exon-9 region of the CD44v protein. This landmark study shows that high levels of CD44v8-10 expressed on gastrointestinal tumor cells confer elevated intracellular GSH and resistance to damage from ROS. This is due to CD44v8-10-dependent recruitment of the xCT subunit of the System xc- antiporter responsible for importing cystine in exchange for glutamate, critical for the regeneration of GSH.	PMID

1. 1. Yoshida GJ, Saya H., Inversed relationship between CD44 variant and c-Myc due to oxidative stress-induced canonical Wnt activation. Biochem Biophys Res Commun. 2014 Jan 10;443(2):622-7. PMID: 24333422

2. 2. Yoshida GJ, Saya H, Zouboulis CC., Three-dimensional culture of sebaceous gland cells revealing the role of prostaglandin E2-induced activation of canonical Wnt signaling. Biochem Biophys Res Commun. 2013 Sep 6;438(4):640- 6. PMID: 23948691

3. 3. Nagano O, Okazaki S, Saya H., Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene. 2013 Jan 21., 1-8. PMID: 23334333

4. 4. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, Onishi N, Masuko T, Yoshizawa K, Kawashiri S, Mukai M, Asoda S, Kawana H, Nakagawa T, Saya H, Nagano O. , xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res. 2013 Mar 15;73(6):1855-66. PMID: 23319806

5. 5. Tsugawa H, Suzuki H, Saya H, Hatakeyama M, Hirayama T, Hirata K, Nagano O, Matsuzaki J, Hibi T., Reactive
   oxygen species-induced autophagic degradation of Helicobacter pylori CagA is specifically suppressed in cancer stem-like cells . Cell Host Microbe. 2012 Dec 13;12(6):764-77. PMID: 23245321

6. 6. Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, ​​Osawa T, Kanki Y, Minami T, Aburatani H, Ohmura M, Kubo A, Suematsu M, Takahashi K, Saya H, Nagano O., Alternative splicing of CD44 mRNA by ESRP1 enhances lung Colonization of metastatic cancer cell. Nat Commun. 2012 Jun 6;3:883. PMID: 22673910

7. 7. Masuko K, Okazaki S, Satoh M, Tanaka G, Ikeda T, Torii R, Ueda E, Nakano T, Danbayashi M, Tsuruoka T, Ohno Y, Yagi H, Yabe N, Yoshida H, Tahara T, Kataoka S, Oshino T, Shindo T, Niwa S, Ishimoto T, Baba H, Hashimoto Y, Saya H, Masuko T., Anti-Tumor Effect against Human Cancer

8. 8. Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H., CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011 Mar 8;19(3):387-400. PMID : 21397861

9. 9. Masuko T, Ohno Y, Masuko K, Yagi H, Uejima S, Takechi M, Hashimoto Y., Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Sci . 2011 Jan;102(1):25-35. PMID: 21040216

10. 10. Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O., CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis . Cancer Sci. 2010 Mar;101(3):673-8. PMID: 20028388

11. 11. Lo M, Wang YZ, Gout PW., The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases, J Cell Physiol. 2008 Jun;215(3):593-602. PMID: 18181196

12. 12. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM., Identification of pancreatic cancer stem cells. Cancer Res. 2007 Feb 1;67(3):1030 -7. PMID: 17283135

13. 13. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF., Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci US A. 2007 Jun 12;104(24):10158-63 PMID: 17548814

14. 14. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE., Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci US A. 2007 Jan 16;104(3):973-8. PMID: 17210912

15. 15. Anne T. Collins,1 Paul A. Berry,1 Catherine Hyde,1 Michael J. Stower,2 and Norman J. Maitland1, Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005 Dec 1;65(23) :10946-51.
    PMID: 16322242

16. 16. Huang Y, Dai Z, Barbacioru C, Sadee W., Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance, Cancer Res. 2005 Aug 15;65(16):7446-54 PMID: 16103098

17. 17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF., Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci US A. 2003 Apr 1;100(7):3983-8. PMID: 12629218

18. 18. Ponta H, Sherman L, Herrlich PA., CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol. 2003 Jan;4(1):33-45. PMID: 12511867

19. 19.Tanabe KK, Ellis LM, Saya H., Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet. 1993 Mar 20;341(8847):725-6. PMID: 8095628

20. 20. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B., CD44 is the principal cell surface receptor for hyaluronate. Cell, Vol. 61. 1303-1313, June 29, 1990, PMID: 1694723